Characterization of the Response to the Kappa Opiate Agonist Salvinorin A in Heal

Kappa 阿片激动剂 Salvinorin A 在治愈中的反应特征

基本信息

  • 批准号:
    8191362
  • 负责人:
  • 金额:
    $ 19.64万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-09-15 至 2013-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Characterization of the response to kappa opiate agonist Salvinorin A in healthy humans Background: Salvinorin A (SA) is the active compound derived from the leaves of the hallucinogenic plant Salvia divinorum, which has been used for centuries in traditional Mexican rituals. More recently, the recreational use of SA for its hallucinogenic effects is increasingly popular amongst young adults. However, there are no controlled data on the effects of SA in humans. SA is unique in being a highly selective agonist solely at the kappa opioid receptor (KOR) and presumably produces its psychotomimetic effects by agonism at this receptor. While there is increasing recognition and concern about the recreational use of SA, there are no controlled studies systematically characterizing its effects in humans. Aims: To characterize the dose-related behavioral, subjective, reinforcing, cognitive, physiological, neuroendocrine and psycho-physiological effects of inhaled SA in healthy humans. Research Design and Methods: 33 healthy subjects will be recruited from the community and after obtaining consent will be carefully screened for participation. Subjects will receive, on 3 separate test days, either placebo or one of two active SA doses (20,005g or 30,005g) through an inhaled route, in a double blind manner. Behavioral, subjective, cognitive and physiological data will be collected throughout each test day. Resting EEG will be obtained immediately after inhalation for 3 minutes with eyes closed. Behavioral measures will include the Clinician Administered Dissociative Symptoms Scale, the Psychotomimetic States Inventory, the Hallucinogen Rating Scale, and the Positive and Negative Syndrome Scale. Subjective effects will be measured on a Visual Analog Scale (VAS). Cognitive measures will include digits forward, digits backward and the letter number sequencing task. Physiological parameters (blood pressure, pulse rate, pulse oximetry) and pupil size will be measured. Blood will be sampled frequently for analysis of SA and plasma prolactin levels. Impact/Significance: The rates of recreational use of Salvinorin A have been rapidly increasing over the last few years and although not federally controlled, a growing number of states have passed legislation controlling its use. However, there is very limited published data on the effects induced by SA in humans. Thus, the growing concern about SA use coupled with the paucity of research in this area presents an urgent need to systematically characterize its dose related subjective, behavioral, cognitive and physiological effects in humans both from a public health as well as regulatory perspective. PUBLIC HEALTH RELEVANCE: There is increasing concern about the recreational use of the hallucinogenic drug Salvinorin A (SA) that is rapidly gaining popularity amongst young adults. The literature on the range effects induced by SA in humans is extremely limited and consists mainly of anecdotal reports from SA users. The lack of data in this area thus presents a compelling need to systematically characterize a wide range of dose related effects of this drug in humans.
描述(由申请人提供):健康人对κ阿片激动剂鼠尾草素A的反应的表征背景:鼠尾草素A(SA)是衍生自致幻植物鼠尾草(Salvia divinorum)的叶的活性化合物,其已在传统墨西哥仪式中使用了几个世纪。最近,SA的致幻作用在年轻人中越来越受欢迎。然而,没有关于SA对人体影响的对照数据。SA的独特之处在于其仅在κ阿片受体(KOR)上是高度选择性激动剂,并且推测其通过激动该受体而产生拟精神病作用。虽然人们越来越认识到和关注SA的娱乐用途,但没有系统地描述其对人类影响的对照研究。目的:描述吸入SA对健康人的剂量相关行为、主观、强化、认知、生理、神经内分泌和心理生理效应。研究设计和方法:将从社区招募33名健康受试者,在获得知情同意后,将仔细筛选是否参与研究。受试者将在3个独立的测试日以双盲方式通过吸入途径接受安慰剂或两种活性SA剂量(20,005 g或30,005 g)之一。将在每个测试日收集行为、主观、认知和生理数据。在闭眼吸入3分钟后立即获取静息EEG。行为测量将包括临床医生管理的分离症状量表、拟精神状态量表、致幻剂评定量表和阳性和阴性综合征量表。将采用视觉模拟量表(VAS)测量主观效应。认知测量将包括数字向前,数字向后和字母数字排序任务。将测量生理参数(血压、脉率、脉搏血氧饱和度)和瞳孔大小。将经常采集血液样本,用于分析SA和血浆催乳素水平。影响/意义:在过去几年中,Salvinorin A的娱乐使用率迅速增加,尽管不受联邦政府控制,但越来越多的州已经通过立法控制其使用。然而,关于SA在人体中诱导的影响的已发表数据非常有限。因此,越来越多的关注SA的使用加上在这一领域的研究的缺乏,提出了一个迫切需要系统地表征其剂量相关的主观,行为,认知和生理影响在人类从公共卫生以及监管的角度。 公共卫生相关性:越来越多的人关注致幻药物Salvinorin A(SA)的娱乐用途,该药物在年轻人中迅速流行。关于SA在人体中引起的范围效应的文献极其有限,主要由SA使用者的轶事报告组成。因此,由于缺乏这方面的数据,迫切需要系统地表征该药物在人体中的广泛剂量相关效应。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MOHINI RANGANATHAN其他文献

MOHINI RANGANATHAN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MOHINI RANGANATHAN', 18)}}的其他基金

Effect of Cannabidiol on Microglial Activation and Central Pain-Sensitization
大麻二酚对小胶质细胞激活和中枢疼痛敏化的影响
  • 批准号:
    10847024
  • 财政年份:
    2019
  • 资助金额:
    $ 19.64万
  • 项目类别:
Effect of Cannabidiol on Microglial Activation and Central Pain-Sensitization
大麻二酚对小胶质细胞激活和中枢疼痛敏化的影响
  • 批准号:
    9895343
  • 财政年份:
    2019
  • 资助金额:
    $ 19.64万
  • 项目类别:
Effect of Cannabidiol on Microglial Activation and Central Pain-Sensitization
大麻二酚对小胶质细胞激活和中枢疼痛敏化的影响
  • 批准号:
    10025663
  • 财政年份:
    2019
  • 资助金额:
    $ 19.64万
  • 项目类别:
Effect of Cannabidiol on Microglial Activation and Central Pain-Sensitization
大麻二酚对小胶质细胞激活和中枢疼痛敏化的影响
  • 批准号:
    10074663
  • 财政年份:
    2019
  • 资助金额:
    $ 19.64万
  • 项目类别:
Multimodal Imaging of Recovery from Cannabis Dependence
大麻依赖恢复的多模态成像
  • 批准号:
    9349476
  • 财政年份:
    2016
  • 资助金额:
    $ 19.64万
  • 项目类别:
Characterization of the Response to the Kappa Opiate Agonist Salvinorin A in Heal
Kappa 阿片激动剂 Salvinorin A 在治愈中的反应特征
  • 批准号:
    8333331
  • 财政年份:
    2011
  • 资助金额:
    $ 19.64万
  • 项目类别:

相似国自然基金

Agonist-GPR119-Gs复合物的结构生物学研究
  • 批准号:
    32000851
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
  • 批准号:
    24K12256
  • 财政年份:
    2024
  • 资助金额:
    $ 19.64万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
  • 批准号:
    24K19176
  • 财政年份:
    2024
  • 资助金额:
    $ 19.64万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
  • 批准号:
    10578068
  • 财政年份:
    2023
  • 资助金额:
    $ 19.64万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 19.64万
  • 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
  • 批准号:
    10650593
  • 财政年份:
    2023
  • 资助金额:
    $ 19.64万
  • 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
  • 批准号:
    10649275
  • 财政年份:
    2023
  • 资助金额:
    $ 19.64万
  • 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
  • 批准号:
    10784209
  • 财政年份:
    2023
  • 资助金额:
    $ 19.64万
  • 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
  • 批准号:
    10734158
  • 财政年份:
    2023
  • 资助金额:
    $ 19.64万
  • 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
  • 批准号:
    10580259
  • 财政年份:
    2023
  • 资助金额:
    $ 19.64万
  • 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
  • 批准号:
    23K05057
  • 财政年份:
    2023
  • 资助金额:
    $ 19.64万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了